Are Late-Stage Deals Beginning to Lose Their Luster?

If there has been anything stable in the pharmaceutical industry, it is an upward trend in late-stage deal prices. And yet, despite the increasing average deal price, the number of big deals is down. In several recent prominent examples, Big Pharma has sharpened its pencils--and said no. The implication: investors will no longer be able to equate late-stage products with blockbuster deals.